Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 04/23/2014 - 12:26pm.

  2. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in ...

    Research Article last updated 07/09/2013 - 3:03pm.

  3. Pharmacotherapy of myelodysplastic syndromes.

    ... molecular pathways that account for disease evolution and clinical heterogeneity is expanded, the arsenal of potential drugs that may ... therapy (approved drug or newer agents still in clinical trial ) is likely to be the most beneficial. While there is no single answer ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Novel therapies for myelodysplastic syndromes.

    ... therapeutic successes have prompted a new wave of clinical trials enrolling patients with myelodysplastic syndromes ... currently in development for MDS, reviewing clinical trial data related to five classes of novel therapeutics: clofarabine, a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... while sparing normal cells. Our purpose is to summarize the clinical activity and safety of intravenous (IV) rigosertib delivered by an ... A multinational pivotal phase 3 randomized clinical trial of rigosertib versus best supportive care for patients with ...

    Research Article last updated 05/22/2014 - 10:23am.

  6. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation and participation on a clinical trial . Bone Marrow ...

    Research Article last updated 02/04/2014 - 1:37pm.

  7. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, ... oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended ...

    Research Article last updated 12/09/2015 - 8:49am.

  8. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation, and participation on a clinical trial . Bone Marrow ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia and a ... therapy, transplantation and participation on a clinical trial . Am. J. Hematol. 87:692-701, 2012. © 2012 Wiley Periodicals, Inc. ...

    Research Article last updated 07/31/2012 - 2:02pm.

  10. Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... enrollment on this protocol may be abandoned if the clinical situation dictates an urgent transplant in the best medical judgment ...

    Clinical Trial last updated 12/19/2017 - 7:55am.